Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dan Legault and CMO Dr. Joseph Stauffer will present on September 13, available for on-demand viewing from 7:00 am ET. The webcast will be accessible for 90 days via the company's website. Antibe focuses on developing safer therapies for inflammatory conditions, with its lead drug otenaproxesul targeting osteoarthritis pain and future aims at inflammatory bowel disease.

TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for a wide range of inflammatory conditions, today announced its participation in the H.C. Wainwright 23^rd Annual Global Investment Conference being held virtually on September 13 - 15. Dan Legault, Antibe’s CEO, and Dr. Joseph Stauffer, Chief Medical Officer, will deliver the Company’s pre-recorded presentation:

Date: Monday, Sept 13, 2021
Time: Available for on-demand viewing from 7:00 am (Eastern Time) onwards

A link to the webcast of the presentation will be available on the News & Events section of the Company’s website at antibethera.com. The webcast will be available on the website for 90 days.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development for the treatment of osteoarthritis pain. Additional assets include a safer alternative to opioids for peri-operative pain, and a GI-sparing alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005313/en/

Antibe Therapeutics Inc.

Christina Cameron

VP Investor Relations

+1 416-577-1443

christina@antibethera.com

Source: Antibe Therapeutics Inc.

FAQ

What is Antibe Therapeutics participating in on September 13, 2021?

Antibe Therapeutics is participating in the H.C. Wainwright 23rd Annual Global Investment Conference.

What time will Antibe Therapeutics' presentation be available?

The presentation will be available for on-demand viewing from 7:00 am ET on September 13, 2021.

Where can I watch the Antibe Therapeutics conference presentation?

The webcast of Antibe's presentation will be available on their website for 90 days.

What is the main focus of Antibe Therapeutics' drug development?

Antibe focuses on developing safer therapies for inflammatory conditions, including a lead drug for osteoarthritis pain.

What is the ticker symbol for Antibe Therapeutics?

The ticker symbol for Antibe Therapeutics is ATBPF on the OTCQX.